S&P MERVAL Index Ends 6.66% Higher at 1268375.74 — Data Talk
The S&P MERVAL Index is up 79165.91 points or 6.66% today to 1268375.74
--Fourth highest close in history
--Largest one-day point gain since Tuesday, Nov. 21, 2023
--Largest one-day percentage gain since Tuesday, March 12, 2024
--Up for three consecutive trading days
--Up 96022.44 points or 8.19% over the last three trading days
--Largest three-day point and percentage gain since Friday, March 22, 2024
--Up four of the past five trading days
--Off 3.63% from its record close of 1316204.45 hit Friday, Feb. 2, 2024
--Today's closing value is the fourth highest this year
--Highest closing value since Friday, Feb. 2, 2024
--Off 3.63% from its 52-week high of 1316204.45 hit Friday, Feb. 2, 2024
--Up 350.17% from its 52-week low of 281752.49 hit Thursday, May 4, 2023
--Rose 323.61% from 52 weeks ago
--Off 3.63% from its 2024 closing high of 1316204.45 hit Friday, Feb 2, 2024
--Up 36.32% from its 2024 closing low of 930419.67 hit Tuesday, Jan. 2, 2024
--Month-to-date it is up 4.52%
--Year-to-date it is up 338671.55 points or 36.43%
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 22, 2024 17:13 ET (21:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm